MisterBlues schreef op 6 december 2020 14:31:
Gaandeweg komen er wel meer geslaagde kapers op de kust van de markt van Pharming.
Tanzeel Akhtar
Fri, December 4, 2020, 6:59 PM GMT+1
BioCryst Pharmaceuticals (NASDAQ: BCRX) shares are trading higher after the company announced the
FDA has approved ORLADEYO for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older.BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases.
BioCryst Pharmaceuticals shares were trading up 14.90% to $5.90. The stock has a 52-week high of $170.75 and a 52-week low of $101.36.